Recall of Valsartan Blood Pressure Medication Expanded to Some Lots of Losartan Over Similar Fears of Carcinogen Tainting

Losartan Recall

As reported by CBS News, Macleods Pharmaceuticals is recalling another 32 lots of its widely used blood pressure medication Losartan that was sold nationwide, after finding the medication contained trace amounts of a probable carcinogen known as NMBA. [Read more…]

Complaint Seeking Medical Monitoring, Economic Reimbursement, and Damages for Personal Injuries Filed in Valsartan Products Liability MDL

Complaint Seeking Medical Monitoring, Economic Reimbursement, and Damages for Personal Injuries Filed in Valsartan Products Liability MDL

On June 17, 2019, Lieff Cabraser and co-counsel filed a Consolidated Amended Class Action Complaint in the consumer fraud litigation against Teva, Major Pharmaceuticals, and Solco Healthcare based on reports that huge amounts of the hypertension drug Valsartan, the generic equivalent of the hypertension drug Diovan, were contaminated with a carcinogen called NDMA. This contamination and the subsequent sale and marketing of the tainted Valsartan perpetrated fraud and violation of warranties on the patient population for Valsartan, as well as violating other laws relating to the safe sale and distribution of prescription drugs. [Read more…]

Rachel Geman Appointed to Plaintiffs’ Steering Committee in National Valsartan Contamination Fraud Litigation

Rachel Geman Appointed to Plaintiffs' Steering Committee in National Valsartan Contamination Fraud Litigation

On May 6, 2019, Lieff Cabraser partner Rachel Geman was appointed to the Plaintiffs’ Economic Reimbursement Steering Committee in the national consumer fraud Valsartan contamination litigation in federal court in New Jersey, In Re: Valsartan Products Liability Litigation, MDL No. 2875. [Read more…]